Non-small cell lung cancer (NSCLC) Clinical Trials in Fairfax, VA

As of June 2026, 77 paid clinical trials are recruiting for Non-small cell lung cancer (NSCLC) in Fairfax, Virginia. Lung cancer research focuses on targeted therapies for specific mutations such as EGFR, ALK, and KRAS, alongside immunotherapy regimens. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Related specialties in Fairfax

Oncology· 536 Lung oncology· 98

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

77 clinical trials for Non-small cell lung cancer (NSCLC)

·Clear filters·↓ Download CSV

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

for Ovarian Cancer

7 locations incl. Birmingham

Sponsor: Tubulis GmbH

Sex: All·Age: 18+

Code: NCT06303505·Phase 1, Phase 2·Recruiting

Apply to this trial

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

22 locations incl. Birmingham

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All·Age: 18+

Code: NCT06343402·Phase 1·Recruiting

Apply to this trial

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

Drug: Osimertinib

36 locations incl. Fountain Valley

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06350097·Phase 3·Recruiting

Apply to this trial

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

for Oncology

17 locations incl. San Francisco

Sponsor: Nested Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT06326411·Phase 1·Recruiting

Apply to this trial

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

for Advanced Solid Tumors With KRAS G12C Mutations

15 locations incl. La Jolla

Sponsor: Frontier Medicines Corporation

Sex: All·Age: 18+

Code: NCT06244771·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

Drug: LY3537982

91 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting

Apply to this trial

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

for Non-small Cell Lung Cancer

Drug: Intismeran autogene

68 locations incl. Anchorage

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06077760·Phase 3·Recruiting

Apply to this trial

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

for Carcinoma, Non-small-Cell Lung

7 locations incl. Newnan

Sponsor: Johnson & Johnson Enterprise Innovation Inc.

Sex: All·Age: 18+

Code: NCT06116786·Phase 1·Recruiting

Apply to this trial

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

for Non-Small Cell Lung Cancer (NSCLC)

Drug: daraxonrasib

21 locations incl. Duarte

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06128551·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

for Cancer

4 locations incl. Austin

Sponsor: OncoResponse, Inc.

Sex: All·Age: 18+

Code: NCT06090266·Phase 1, Phase 2·Recruiting

Apply to this trial

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

for Non-Small Cell Lung Cancer

9 locations incl. Duarte

Sponsor: Pierre Fabre Medicament

Sex: All·Age: 18+

Code: NCT06043817·Phase 1, Phase 2·Recruiting

Apply to this trial

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

for Non-small Cell Lung Cancer (NSCLC)

17 locations incl. Sacramento

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06040541·Phase 1·Recruiting

Apply to this trial

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

for Non Small Cell Lung Cancer

24 locations incl. Beverly Hills

Sponsor: SystImmune Inc.

Sex: All·Age: 18+

Code: NCT05983432·Phase 1·Recruiting

Apply to this trial

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

for Non Small Cell Lung Cancer

46 locations incl. Dothan

Sponsor: OncoC4, Inc.

Sex: All·Age: 18+

Code: NCT05671510·Phase 3·Recruiting

Apply to this trial

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

for Non Small Cell Lung Cancer

13 locations incl. Santa Monica

Sponsor: Tango Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05887492·Phase 1, Phase 2·Recruiting

Apply to this trial

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

for Non-small Cell Lung Cancer

10 locations incl. Gilbert

Sponsor: Institut de Recherches Internationales Servier

Sex: All·Age: 18+

Code: NCT05786924·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

for Solid Tumor, Adult

13 locations incl. Los Angeles

Sponsor: GV20 Therapeutics

Sex: All·Age: 18+

Code: NCT05669430·Phase 1, Phase 2·Recruiting

Apply to this trial

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

for Advanced or Metastatic Solid Tumors

11 locations incl. Scottsdale

Sponsor: Incendia Therapeutics

Sex: All·Age: 18+

Code: NCT05753722·Phase 1·Recruiting

Apply to this trial

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

for Adenocarcinoma of Lung

6 locations incl. Beverly Hills

Sponsor: Lantern Pharma Inc.

Sex: All·Age: 18+

Code: NCT05456256·Phase 2·Recruiting

Apply to this trial

MYLUNG Consortium Part 3: Observational Study

for Carcinoma, Non-Small-Cell Lung

17 locations incl. Daphne

Sponsor: US Oncology Research

Sex: All·Age: 18+

Code: NCT05885698·Recruiting

Apply to this trial

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

for High Grade Epithelial Ovarian Cancer

37 locations incl. Phoenix

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT05579366·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

for Carcinoma, Non-small-Cell Lung

Drug: Amivantamab

26 locations incl. La Jolla

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05498428·Phase 2·Recruiting

Apply to this trial

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

for Carcinoma, Non-Small-Cell Lung

25 locations incl. Birmingham

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT05208762·Phase 1·Recruiting

Apply to this trial

A Study of EP0031 in Patients With Advanced RET-altered Malignancies

for Advanced Solid Tumor

Drug: EP0031

18 locations incl. Los Angeles

Sponsor: Ellipses Pharma

Sex: All·Age: 18+

Code: NCT05443126·Phase 1, Phase 2·Recruiting

Apply to this trial

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

for Non Small Cell Lung Cancer

6 locations incl. Huntersville

Sponsor: Phanes Therapeutics

Sex: All·Age: 18+

Code: NCT05431270·Phase 1, Phase 2·Recruiting

Apply to this trial

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

for Non-Small Cell Lung Cancer

5 locations incl. Lexington

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT05142189·Phase 1·Recruiting

Apply to this trial

Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

for NSCLC

21 locations incl. Davis

Sponsor: Lung Cancer Mutation Consortium

Sex: All·Age: All ages

Code: NCT04712877·Recruiting

Apply to this trial

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

for Mesothelioma

25 locations incl. Phoenix

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT05245500·Phase 1·Recruiting

Apply to this trial

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

for Non-small Cell Lung Cancer (NSCLC)

21 locations incl. Orange

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT05379985·Phase 1, Phase 2·Recruiting

Apply to this trial

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

25 locations incl. Little Rock

Sponsor: AstraZeneca

Sex: All·Age: 18 - 95

Code: NCT05061550·Phase 2·Recruiting

Apply to this trial

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

for Advanced Solid Tumor

27 locations incl. Tucson

Sponsor: Synthekine

Sex: All·Age: 18+

Code: NCT05098132·Phase 1, Phase 2·Recruiting

Apply to this trial

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

for Advanced Solid Tumor

9 locations incl. Fullerton

Sponsor: TORL Biotherapeutics, LLC

Sex: All·Age: 18+

Code: NCT05103683·Phase 1·Recruiting

Apply to this trial

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

for Non-Small Cell Lung Cancer

Drug: Bevacizumab

18 locations incl. Duarte

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT05005403·Phase 1·Recruiting

Apply to this trial

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer

38 locations incl. Duarte

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT04302025·Phase 2·Recruiting

Apply to this trial

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

for Advanced Solid Tumor

32 locations incl. Irvine

Sponsor: PMV Pharmaceuticals, Inc

Sex: All·Age: 12+

Code: NCT04585750·Phase 1, Phase 2·Recruiting

Apply to this trial

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

for Solid Tumor

6 locations incl. Gilbert

Sponsor: ImmVira Pharma Co. Ltd

Sex: All·Age: 18+

Code: NCT04370587·Phase 1, Phase 2·Recruiting

Apply to this trial

Study of NEO-201 in Solid Tumors Expansion Cohorts

for Non Small Cell Lung Cancer

2 locations incl. Bethesda

Sponsor: Precision Biologics, Inc

Sex: All·Age: 18+

Code: NCT03476681·Phase 1, Phase 2·Recruiting

Apply to this trial